Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Published:2024-05 Issue:5 Volume:90 Page:986-993
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew^ORCID,Draelos Zoe D.,Stein Gold Linda,Alonso-Llamazares Javier,Bhatia Neal,DuBois Janet,Forman Seth B.,Gooderham Melinda,Green Lawrence,Guenthner Scott T.,Hebert Adelaide A.,Lain Edward,Moore Angela Y.,Papp Kim A.,Zirwas Matthew,Kato Saori,Snyder Scott,Krupa David,Burnett Patrick,Berk David R.,Chu David H.

Publisher

Elsevier BV

Reference18 articles.

1. Seborrheic dermatitis: lifetime detection rates;Palamaras;J Eur Acad Dermatol Venereol,2012

2. Patient and healthcare provider perspectives on the disease burden of seborrheic dermatitis in the United States: results from a national survey;Chovatiya,2023

3. Personality traits and common psychiatric conditions in patients with seborrheic dermatitis;Gül;Arch Clin Psychiatry,2017

4. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis;Peyrí;Actas Dermosifiliogr,2007

5. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level;Szepietowski;Mycoses,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Topical Therapy for Atopic Dermatitis;Dermatologic Clinics;2024-10

2. Roflumilast in Dermatology: A Newer Phosphodiesterase-4 Inhibitor;Indian Journal of Dermatology;2024-09-13

3. Moderne topische Arzneimittel – neue Entwicklungen in Galenik und Pharmakologie;Die Dermatologie;2024-08-27

4. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases;Frontiers in Pharmacology;2024-06-10

5. Topical moisturizer with rose stem cell‐derived exosomes (RSCEs) for recalcitrant seborrheic dermatitis: A case report with 6 months of follow‐up;Journal of Cosmetic Dermatology;2024-06-03